The 28-year-old CEO of Ascendance Biomedical, a controversial medical startup, was found dead in a Washington, D.C. flotation therapy tank on Sunday, authorities said.

Aaron Traywick was found dead in a D.C. spa, the Metropolitan Police Department told VICE News on Tuesday. A family member reportedly added Traywick had been found in a flotation therapy tank. While the investigation is ongoing, police said early evidence does not suggest foul play, VICE reported.

Ascendance Biomedical’s goal is to make “cutting-edge biomedical technologies available for everyone” by skirting traditional research protocols. The company is currently researching compounds that promise to potentially eliminate HIV/AIDS and herpes, slow the aging process and more. The company’s employees are known for testing these experimental therapies on themselves. In fact, just a few months ago, Traywick made headlines for injecting himself with a largely untested herpes treatment while on stage at a conference.

The Food and Drug Administration released a consumer advisory shortly after the company posted a video that showed individuals self-administering a gene therapy it had developed, the MIT Technology Review reports, though it did not mention Ascendance by name.

Traywick had not been in touch with anyone at Ascendance Biomedical for weeks leading up to his death, and the company was consumed by disagreements over its direction and guiding principles, according to VICE. “We all lost touch with him. It was radio silence,” Andreas Stuermer, a researcher at the company, told the site. “It was more than four weeks ago.”

Stuermer added that, “The future is difficult to predict. He was willing to go where lots of people were afraid to go. I don’t have the perfect answer to this, but stuff will go on.”

Get The Brief. Sign up to receive the top stories you need to know right now. Please enter a valid email address. Sign Up Now Check the box if you do not wish to receive promotional offers via email from TIME. You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy . This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Thank you! For your security, we've sent a confirmation email to the address you entered. Click the link to confirm your subscription and begin receiving our newsletters. If you don't get the confirmation within 10 minutes, please check your spam folder.

Write to Jamie Ducharme at jamie.ducharme@time.com.